Neurocrine biosciences presents one-year data showing sustained efficacy of crenessity® (crinecerfont) in adult patients, at endo 2025

One-year data from cahtalyst™ adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia results build upon previously reported one-year data from cahtalyst™ pediatric study san diego , july 14, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced the presentation of new one-year data from the cahtalyst™ adult study of crenessity® (crinecerfont) showing that patients achieved lasting, more physiologic glucocorticoid doses, while adrenocorticotropic hormone, 17-hydroxyprogesterone and androstenedione remained at or below baseline levels. these data complement the recently announced cahtalyst™ pediatric one-year results and were presented at the endocrine society's annual meeting, endo 2025, that is taking place july 12-15 in san francisco.
NBIX Ratings Summary
NBIX Quant Ranking